Close Menu
News JournosNews Journos
  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Turkey Reports
  • Money Watch
  • Health
Editors Picks

Whistleblower’s Lawyer Files Suit Over Revoked Security Clearance in Trump Impeachment Case

May 6, 2025

UAE and U.S. Establish $1.4 Trillion Investment Framework Over 10 Years

March 22, 2025

Former Aide Critiques Trump and GOP’s Stance on Millionaire Tax Hikes

May 8, 2025

Trump Mediates Ceasefire Agreement Between Israel and Iran

June 23, 2025

House GOP Cancels Late-Night Session Amid Republican Revolt on Trump Budget Bill

May 18, 2025
Facebook X (Twitter) Instagram
Latest Headlines:
  • Israel Commemorates Two Years Since Hamas Attack Amid Ongoing Gaza War Reflections
  • Stellantis Faces Major Data Breach Affecting Third-Party Information
  • FBI Arrests Dozens of Gang Leaders in Major Mexican Mafia Operation in Los Angeles
  • UK Police Disrupt Gang Allegedly Smuggling 40,000 Stolen Phones to China
  • Tesla Cuts Model Y Standard Price Below $40,000
  • Turkey to Supply Rare Earth Elements to the U.S. Amid Court of Accounts Findings
  • U.S.-Mexico Border Illegal Crossings Reach Lowest Level Since 1970
  • Nexstar Acquires Tegna for $6.2 Billion
  • Bob Ross Paintings Auctioned to Support Public TV Stations Following Funding Cuts
  • Excitement and Concerns Surround OpenAI’s Sora 2 and New AI Video Tools
  • Netanyahu Commemorates Two Years Since October 7 Attack, Declares Resilience Against Adversaries
  • Helicopter Crash on Sacramento Freeway Leaves Three Critically Injured
  • Global M&A Activity Surges Amid Megadeals and Rate-Cut Expectations
  • Tech Companies Report Earnings Amid Market Fluctuations
  • Gold Prices Surge, Prompting Warnings from Jewelry Industry
  • Israel Government Labels Zohran Mamdani as Hamas Spokesperson
  • CoolKicks Founder Arrested for Receiving Stolen Nike Goods Worth $500K
  • Hurricane Priscilla Strengthens Over Pacific, Forecast Path Revealed
  • Effective Methods for Detecting and Removing Malware from Infected Mac Computers
  • Portland Faces Escalating Tensions Amid Claims of ‘Domestic Occupation’
Facebook X (Twitter) Instagram
News JournosNews Journos
Subscribe
Wednesday, October 8
  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Turkey Reports
  • Money Watch
  • Health
News JournosNews Journos
You are here: News Journos » Business » Amgen’s MariTide Enters Phase Three Trials for Weight Loss
Amgen's MariTide Enters Phase Three Trials for Weight Loss

Amgen’s MariTide Enters Phase Three Trials for Weight Loss

News EditorBy News EditorMarch 5, 2025 Business 6 Mins Read

Amgen has made significant strides in the weight-loss drug arena by initiating late-stage trials for its experimental injection, MariTide. As the company aims to penetrate the burgeoning obesity treatment market, MariTide will undergo evaluation in two critical studies involving thousands of participants, targeting varying patient profiles. This development is particularly crucial as existing competitors like Novo Nordisk and Eli Lilly currently dominate the market with their GLP-1-based treatments.

Article Subheadings
1) Overview of MariTide and Its Development
2) The Role of GLP-1 Receptor Agonists
3) Details of the Latest Clinical Trials
4) Market Prospects and Competitive Landscape
5) Future Implications for Weight Loss Treatments

Overview of MariTide and Its Development

Amgen recently announced the commencement of late-stage trials for its experimental weight loss drug, MariTide. As a potential game-changer in the obesity medication sector, MariTide is designed to be administered via a monthly injection, aligning itself as a contender against already established treatments by major players like Novo Nordisk and Eli Lilly. According to Dr. Jay Bradner, Amgen’s executive vice president of research and development, the initiation of these trials marks a significant milestone in the MARITIME program, aiming to evaluate the drug’s efficacy in aiding weight loss in various patient groups.

Rooted in advanced biotechnology, MariTide diverges from existing treatments by employing a unique mechanism that combines peptide antibodies to activate gut hormone receptors. The management at Amgen believes that this innovative approach may not only enhance weight loss results but also reduce the plateau effect commonly observed in similar therapies.

The Role of GLP-1 Receptor Agonists

GLP-1 receptor agonists play a pivotal role in the effectiveness of weight loss drugs, mimicking hormones produced in the gut to promote satiety and regulate blood sugar. Currently, medications such as those from Novo Nordisk and Eli Lilly utilize this approach, causing market success in treating obesity. Statistics indicate that around 6% of U.S. adults, equating to more than 15 million individuals, were utilizing prescriptions for GLP-1s as of May. The demand for such treatments is expected to increase, with growing projections for the market value to surpass $150 billion annually by the 2030s.

MariTide is drawing interest as it operates within this framework but introduces a distinctive composition that involves a peptide antibody conjugate. This design intends to target specific pathways in appetite regulation, setting it apart from existing medications that activate multiple hormone pathways indiscriminately. Amgen’s strategic focus on a dual-action mechanism, leveraging the benefits of GLP-1 while blocking receptors associated with GIP, positions MariTide as a potentially effective alternative.

Details of the Latest Clinical Trials

The newly launched phase three trials aim to evaluate the effects of MariTide on different patient demographics. One of the ongoing studies is focusing on approximately 3,500 obese individuals who do not have Type 2 diabetes. The second trial involves 999 participants who are also obese but do have Type 2 diabetes. The trials are strategically structured to analyze the percentage of weight loss achieved over a 72-week period, scrutinizing various dosages of MariTide to assess its effectiveness and safety profile.

A notable aspect of these trials is the use of dose escalation strategies, wherein patients will begin with a lower dosage that may increase based on their response to the treatment. This flexible approach is designed to enhance patient tolerability and maximize therapeutic outcomes. The excitement surrounding these trials is grounded in previous phase two study results, which reported an average weight loss of up to 20% over a year for obese individuals and a decrease of up to 17% for those with Type 2 diabetes, without encountering a weight loss plateau.

Market Prospects and Competitive Landscape

As the competition within the obesity drug market intensifies, MariTide’s entry represents a significant opportunity for Amgen. The existing landscape is dominated by drugs like Zepbound from Eli Lilly and Wegovy from Novo Nordisk, which are also weekly injectables. However, their success underscores the need for a broader range of treatment options tailored to the diverse patient population. Analysts are keeping a close watch on MariTide, considering that its unique formulation may widen the therapeutic palette available for clinicians.

Market analysts believe that if MariTide meets or exceeds expectations based on phase two findings, it could significantly chip away at the market share held by competitor products. Given that Amgen is set to release additional benchmarks from ongoing trials and past studies, investors and healthcare professionals alike are keen on how this product will affect the obesity treatment paradigm.

Future Implications for Weight Loss Treatments

The potential introduction of MariTide to the market heralds a new era in weight management therapies, where innovative designs can alter traditional treatment approaches. With obesity rates increasing globally, the advent of more effective and tailored interventions is critical. Amgen has positioned itself strategically to leverage the soon-to-be-available data from its trials, which could resonate comprehensively with healthcare providers looking to optimize patient outcomes.

Moreover, the anticipated positive results could not only impact Amgen’s revenue substantially but may also spur further advancements and research within the weight loss drug space. Such developments could lead to increased competition, ultimately benefitting patients seeking effective solutions for obesity management.

No. Key Points
1 Amgen has initiated late-stage trials for its experimental weight loss injection, MariTide.
2 MariTide aims to compete in the growing market for GLP-1 inhibitors, currently dominated by Novo Nordisk and Eli Lilly.
3 The trials will evaluate weight loss effectiveness in approximately 4,500 participants with varying obesity profiles.
4 Novel dosing strategies and results from previous studies showcase MariTide’s potential effectiveness.
5 Future results from these trials could significantly impact Amgen’s position in the lucrative obesity treatment market.

Summary

The initiation of late-stage trials for MariTide signals an ambitious undertaking by Amgen in the competitive weight-loss drug market. With obesity being a critical health concern, the implications of this drug could resonate widely across various patient demographics. As results from these trials become public, both the medical community and investors are likely to be attentive to the potential disruptions MariTide may bring to the current landscape of obesity treatment.

Frequently Asked Questions

Question: What is MariTide and how does it work?

MariTide is an experimental weight loss injection being developed by Amgen that employs a unique peptide antibody conjugate mechanism to target appetite regulation.

Question: How does MariTide compare to existing GLP-1 medications?

Unlike existing GLP-1 medications, MariTide utilizes a dual-action approach that activates GLP-1 receptors while blocking GIP receptors, potentially improving efficacy in managing obesity.

Question: What are the expectations for MariTide’s market entry?

Should the ongoing trials produce favorable results, MariTide is expected to carve a significant niche in the obesity treatment market, potentially challenging the current leaders in the field.

Amgens Business Ethics Business Growth Business News Business Technology Consumer Trends Corporate Finance Corporate Strategy Economic Outlook Enters Entrepreneurship Global Business Innovation Investment Opportunities Leadership Loss Management MariTide Market Trends Mergers & Acquisitions Phase Retail Business Small Business Startups Supply Chain Trials Weight
Share. Facebook Twitter Pinterest LinkedIn Email Reddit WhatsApp Copy Link Bluesky
News Editor
  • Website

As the News Editor at News Journos, I am dedicated to curating and delivering the latest and most impactful stories across business, finance, politics, technology, and global affairs. With a commitment to journalistic integrity, we provide breaking news, in-depth analysis, and expert insights to keep our readers informed in an ever-changing world. News Journos is your go-to independent news source, ensuring fast, accurate, and reliable reporting on the topics that matter most.

Keep Reading

Business

Gold Prices Surge, Prompting Warnings from Jewelry Industry

6 Mins Read
Business

Constellation Brands Reports Q2 2026 Earnings Results

4 Mins Read
Business

Taylor Swift’s ‘The Life of a Showgirl’ Vinyl Exempts Tariffs

6 Mins Read
Business

Tesla and GM Drive Record U.S. EV Sales Amid Federal Incentives Expiration

6 Mins Read
Business

Auto Stocks Surge on News of Tariff Relief for U.S. Vehicles

5 Mins Read
Business

Musk Advocates for Canceling Netflix Amid Ongoing Controversies

5 Mins Read
Journalism Under Siege
Editors Picks

Harris Criticizes Trump and Musk, Warns of Threats to Democracy in NAACP Speech

February 24, 2025

Congressional Democrats Advocate for New Oversight Body for Trump Administration

July 9, 2025

Trump Supports Musk’s Controversial DOGE Productivity Email with Ultimatum

February 24, 2025

Federal Judge Allows Trump to Utilize Alien Enemies Act for Deportations With Notification

May 13, 2025

Fired FTC Commissioner Warns Trump Administration’s Actions Threaten Market Stability

March 19, 2025

Subscribe to News

Get the latest sports news from NewsSite about world, sports and politics.

Facebook X (Twitter) Pinterest Vimeo WhatsApp TikTok Instagram

News

  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Money Watch

Journos

  • Top Stories
  • Turkey Reports
  • Health
  • Tech
  • Sports
  • Entertainment

COMPANY

  • About Us
  • Get In Touch
  • Our Authors
  • Privacy Policy
  • Terms and Conditions
  • Accessibility

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

© 2025 The News Journos. Designed by The News Journos.

Type above and press Enter to search. Press Esc to cancel.

Ad Blocker Enabled!
Ad Blocker Enabled!
Our website is made possible by displaying online advertisements to our visitors. Please support us by disabling your Ad Blocker.
Go to mobile version